Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 119

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 119
---
afenoquine; and (iii) celgosivir. The Company’s
headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.

Initial Public Offering

On July 14, 2023, the Company closed its initial
public offering consisting of 23,585 units at a price of $318.00 per unit for $6,454,325 in net proceeds, after deducting the underwriting
discount and commission and other estimated offering expenses paid by the Company at closing (the “IPO”). Each unit consisted
of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $365.70 per share (a
“Tradeable Warrant”), and one non-tradeable warrant to purchase one share of the Company’s common stock at an exercise
price of $381.60 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants were immediately
exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028).

The Company granted the underwriters a 45-day
over-allotment option to purchase up to 3,538 shares of the Company’s common stock at a price of $316.80 per share and/or 3,538
Tradeable Warrants at a price of $0.60 per Tradeable Warrant and/or 3,538 Non-tradeable Warrants at $0.60 per Non-tradeable Warrant,
or any combination thereof (the “IPO Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment
and purchased an additional 1,678 Tradeable Warrants and 1,678 Non-tradeable Warrants. The Company also issued to the underwriters warrants
to purchase 1,416 shares of the Company’s common stock, at an exercise price of $349.80 per share, equal to 110% of the offering
price per unit (the “IPO Representative Warrants”). The IPO Representative Warrants are exercisable for a period of five
years from the date of issuance (July 14, 2023 to July 14, 2028).

The units were offered and sold pursuant to the
Company’s Registration Statement on Form S-1, as amended (File No. 333-269483